The translational alignment of our preclinical findings with existing and emerging clinical paradigms positions the Brca1co/coMMTV-Cre mouse as an optimal platform for accelerated evaluation of next‐generation combination therapies targeting BRCA1‐deficient breast cancer. Here, BRCA1 is linked to breast cancer.